Results presented on Tuesday at the American Association for Cancer Reserch include data on the combined use of tissue and ...

A review now published in the Journal of Experimental & Clinical Cancer Research offers a sweeping and authoritative ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the results of a study ...

Perlman Department of Dermatology at NYU Grossman School of Medicine ... “The discovery of cell-free, circulating tumor DNA (ctDNA) as a direct, albeit imperfect, measurement of tumor ...

A Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions Mar. 17, 2025 — In the continuing evolution of personalized medicine ... detecting circulating tumor cells in the ...

Cancer is one of the leading causes of death globally, with nearly 20 million new cases and 9.7 million deaths in 2022. Early detection plays a crucial role in reducing cancer-related morbidity ...

Encompass Health tapped Patrick Tuer to serve as its first COO. He has held various leadership positions, including group ...

The team is exploring whether biomarker testing could also identify patients who benefit more from immune checkpoint inhibitors after radiation.

A new, error-corrected method for detecting cancer from blood ... of the Englander Institute for Precision Medicine and associate professor of medicine and of cell and developmental biology ...

circulating tumor cells at single-cell resolution, RNA transcriptomics and proteomics. Marking its evolution from a genomics-based diagnostic company to an AI-powered leader in precision oncology, the ...

Detection requires precision because most RNA circulating in the bloodstream originates from blood-forming cells rather than tumors. Rare tumor-derived RNA molecules are often masked by the ...